Imricor Medical Systems Future Growth
Future criteria checks 2/6
Imricor Medical Systems is forecast to grow revenue at 88.6% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Medical Equipment earnings growth | 16.0% |
Revenue growth rate | 88.6% |
Future return on equity | -187.7% |
Analyst coverage | Low |
Last updated | 04 Dec 2024 |
Recent future growth updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now
May 08Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet?
Jun 17Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely
Jul 08Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?
Mar 23We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely
May 09When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?
Feb 28We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully
Jan 24What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?
Dec 02What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition
Aug 18Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR)
Jun 25Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 20 | N/A | -10 | -9 | 1 |
12/31/2025 | 9 | N/A | -14 | -13 | 1 |
12/31/2024 | 4 | N/A | -16 | -15 | 1 |
6/30/2024 | 1 | -20 | -15 | -15 | N/A |
3/31/2024 | 1 | -21 | -14 | -14 | N/A |
12/31/2023 | 1 | -23 | -13 | -13 | N/A |
9/30/2023 | 1 | -20 | -14 | -14 | N/A |
6/30/2023 | 0 | -17 | -14 | -14 | N/A |
3/31/2023 | 1 | -17 | -16 | -15 | N/A |
12/31/2022 | 1 | -17 | -17 | -17 | N/A |
9/30/2022 | 1 | -18 | -17 | -17 | N/A |
6/30/2022 | 1 | -20 | -17 | -17 | N/A |
3/31/2022 | 1 | -20 | -18 | -17 | N/A |
12/31/2021 | 1 | -20 | -18 | -17 | N/A |
9/30/2021 | 1 | -18 | -17 | -16 | N/A |
6/30/2021 | 1 | -17 | -16 | -15 | N/A |
3/31/2021 | 1 | -15 | -15 | -14 | N/A |
12/31/2020 | 1 | -12 | -13 | -12 | N/A |
9/30/2020 | 1 | -13 | -12 | -11 | N/A |
6/30/2020 | 1 | -14 | -10 | -9 | N/A |
3/31/2020 | 1 | -14 | -9 | -8 | N/A |
12/31/2019 | 1 | -13 | -7 | -7 | N/A |
9/30/2019 | 1 | -11 | -6 | -6 | N/A |
6/30/2019 | 0 | -8 | -6 | -5 | N/A |
3/31/2019 | 1 | -7 | -5 | -5 | N/A |
12/31/2018 | 1 | -5 | -5 | -5 | N/A |
12/31/2017 | 0 | -5 | N/A | -4 | N/A |
12/31/2016 | 1 | -4 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if IMR's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if IMR's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if IMR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IMR's revenue (88.6% per year) is forecast to grow faster than the Australian market (5.8% per year).
High Growth Revenue: IMR's revenue (88.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMR is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 23:46 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Imricor Medical Systems, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Elyse Shapiro | Bell Potter |
Sarah Mann | MA Moelis Australia Securities Pty Ltd |
Scott Power | Morgans Financial Limited |